KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $999000.0.

  • TherapeuticsMD's Net Cash Flow rose 150704.23% to $999000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 21612.19%. This contributed to the annual value of $1.2 million for FY2024, which is 10587.05% up from last year.
  • TherapeuticsMD's Net Cash Flow amounted to $999000.0 in Q3 2025, which was up 150704.23% from $381000.0 recorded in Q2 2025.
  • TherapeuticsMD's Net Cash Flow's 5-year high stood at $57.1 million during Q1 2021, with a 5-year trough of -$140.8 million in Q2 2022.
  • Its 5-year average for Net Cash Flow is -$9.0 million, with a median of -$229000.0 in 2024.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 551514.08% in 2021, then plummeted by 43753.67% in 2022.
  • Quarter analysis of 5 years shows TherapeuticsMD's Net Cash Flow stood at $47.8 million in 2021, then tumbled by 270.95% to -$81.8 million in 2022, then surged by 96.38% to -$3.0 million in 2023, then skyrocketed by 100.57% to $17000.0 in 2024, then soared by 5776.47% to $999000.0 in 2025.
  • Its last three reported values are $999000.0 in Q3 2025, $381000.0 for Q2 2025, and $699000.0 during Q1 2025.